<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472418</url>
  </required_header>
  <id_info>
    <org_study_id>DFN-15-CD-002</org_study_id>
    <nct_id>NCT02472418</nct_id>
  </id_info>
  <brief_title>Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches</brief_title>
  <official_title>A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Crossover Study Evaluating Efficacy of DFN-15 in Patients With Migraine Headache With or Without Aura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <brief_summary>
    <textblock>
      Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of&#xD;
      migraine headaches.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2015</start_date>
  <completion_date type="Actual">May 5, 2016</completion_date>
  <primary_completion_date type="Actual">December 1, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Free, defined as a score of &quot;0&quot; on a numerical scale of &quot;0&quot; to &quot;3&quot;</measure>
    <time_frame>2 hour</time_frame>
    <description>Percentage of subjects who are migraine headache free at 2 hours after taking study drug administration</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>DFN-15 120 mg (treatment A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFN-15 120 mg (treatment A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFN-15 240 mg (treatment B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFN-15 240 mg (treatment B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (treatment C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (treatment C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 Dose A (treatment A)</intervention_name>
    <description>DFN-15 Dose A administered</description>
    <arm_group_label>DFN-15 120 mg (treatment A)</arm_group_label>
    <other_name>DFN-15 120 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 Dose B (treatment B)</intervention_name>
    <description>DFN-15 Dose B administered</description>
    <arm_group_label>DFN-15 240 mg (treatment B)</arm_group_label>
    <other_name>DFN-15 240 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (treatment C)</intervention_name>
    <description>Placebo administered</description>
    <arm_group_label>Placebo (treatment C)</arm_group_label>
    <other_name>Placebo (no active ingredient)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of episodic migraine (as defined by International&#xD;
             Classification of Headache Disorders [ICHD]-228) who experience an average of 2 to 6&#xD;
             migraine attacks a month for the past 12 months with no more than 14 headache days per&#xD;
             month, and with at least 48 hours of headache-free time between migraine attacks;&#xD;
&#xD;
          2. Patients with onset of migraine with or without aura before age 50;&#xD;
&#xD;
          3. Patients who have migraine with or without aura, in which the aura cannot last longer&#xD;
             than 60 minutes;&#xD;
&#xD;
          4. Patients who report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain&#xD;
             severity scale.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with medication overuse headache (MOH) as defined by ICHD-228:&#xD;
&#xD;
               -  Opioids ≥ 10 days a month during the 90 days prior to screening&#xD;
&#xD;
               -  Combination medications (eg, Fiorinal® ≥ 10 days a month)&#xD;
&#xD;
               -  Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications &gt; 14&#xD;
                  days a month during the 90 days prior to screening&#xD;
&#xD;
               -  Triptans or ergots ≥ 10 days a month during the 90 days prior to screening&#xD;
&#xD;
          2. Patients on chronic warfarin sodium;&#xD;
&#xD;
          3. Patients taking monoamine oxidase-A (MAO-A) inhibitors;&#xD;
&#xD;
          4. Patients on unstable dosages of chronic medications during the 3 months prior to and&#xD;
             through screening, or who are not willing or able to maintain a stable pre-study dose&#xD;
             throughout study participation;&#xD;
&#xD;
          5. Patients with more than 6 migraine attacks a month and/or more than 14 headache days a&#xD;
             month (based upon patient self-report);&#xD;
&#xD;
          6. Patients with hemiplegic migraine or migraine with brain stem aura or other forms of&#xD;
             neurologically complicated migraine;&#xD;
&#xD;
          7. Patients with atypical aura;&#xD;
&#xD;
          8. Patients with prolonged aura (more than 1 hour).&#xD;
&#xD;
          9. Patients with a history of stroke or transient ischemic attack;&#xD;
&#xD;
         10. Patients with a history of migralepsy or a concurrent diagnosis of seizure disorder;&#xD;
&#xD;
         11. Patients who cannot differentiate between a migraine headache and a tension-type or&#xD;
             cluster headache or any other non-migraine headache;&#xD;
&#xD;
         12. Patients with a history of more than 10 tension-type headaches per month;&#xD;
&#xD;
         13. Patients with a history of cluster headache;&#xD;
&#xD;
         14. Patients with a diagnosis of ICHD-2 &quot;probable migraine&quot;;&#xD;
&#xD;
         15. Patients with uncontrolled hypertension (screening blood pressure ≥ 140/90 mmHg&#xD;
             despite appropriate pharmacotherapy);&#xD;
&#xD;
         16. Patients with severe renal impairment (defined as serum creatinine &gt; 1.9 mg/dL);&#xD;
&#xD;
         17. Patients with serum total bilirubin &gt; 1.9 mg/dL;&#xD;
&#xD;
         18. Patients with serum aspartate aminotransferase (AST), alanine aminotransferase (ALT),&#xD;
             or alkaline phosphatase &gt; 3 times the upper limit of normal;&#xD;
&#xD;
         19. Patients with positive serology for human immunodeficiency virus (HIV), Hepatitis B&#xD;
             surface antigen, Hepatitis C antibody.&#xD;
&#xD;
         20. Patients with a history of alcohol or substance abuse (including marijuana and medical&#xD;
             marijuana) within 1 year that would compromise data collection;&#xD;
&#xD;
         21. Patients with a history of or current neurological or psychiatric impairment, or&#xD;
             cognitive dysfunction that, in the opinion of the investigator, would compromise data&#xD;
             collection;&#xD;
&#xD;
         22. Patients with any other medical condition that, in the judgment of the investigator or&#xD;
             medical monitor, would confound the objectives of the study (eg, cancer history&#xD;
             [except basal cell carcinoma], systemic lupus erythematosus);&#xD;
&#xD;
         23. Patients who have participated in a clinical trial involving any medication during the&#xD;
             past 30 days or 5 half-lives of the study medication, whichever is longer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corporation</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Head Pain &amp; Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest/ A Division of Banyan Group, Inc.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Munjal S, Bennett A. Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study. Neuropsychiatr Dis Treat. 2017 Nov 7;13:2797-2802. doi: 10.2147/NDT.S151834. eCollection 2017.</citation>
    <PMID>29158678</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <disposition_first_submitted>May 15, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 17, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 22, 2018</disposition_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

